{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=12", "query": { "condition": "Refractory Malignancy", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 5765, "total_pages": 577, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T18:29:36.469Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06789159", "title": "A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed", "Epstein-Barr Virus (EBV) Infection" ], "interventions": [ { "name": "VK-2019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierluigi Porcu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-08-21", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789159" }, { "nct_id": "NCT04019288", "title": "AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Batiraxcept", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2019-12-03", "completion_date": "2024-10-24", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019288" }, { "nct_id": "NCT02787369", "title": "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Chronic Lymphoid Leukemia" ], "interventions": [ { "name": "ACY-1215", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-05", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02787369" }, { "nct_id": "NCT00719888", "title": "Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Burkitt Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Follicular Lymphoma", "Lymphoblastic Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Non-Hodgkin Lymphoma", "Plasma Cell Myeloma", "Prolymphocytic Leukemia", "Refractory Anemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Double-Unit Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 135, "start_date": "2005-11-18", "completion_date": "2024-12-19", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 3, "location_summary": "Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719888" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT03291054", "title": "Epacadostat and Pembrolizumab in Patients With GIST", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • New York, New York", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291054" }, { "nct_id": "NCT02020941", "title": "Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Attaya Suvannasankha", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-09", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020941" }, { "nct_id": "NCT00305773", "title": "Vorinostat in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Erythroid Leukemia (M6)", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Acute Promyelocytic Leukemia (M3)", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Cytopenia With Multilineage Dysplasia", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2006-01", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305773" }, { "nct_id": "NCT01646762", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2012-11-05", "completion_date": "2015-10-27", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646762" }, { "nct_id": "NCT05188170", "title": "Niclosamide in Pediatric Patients With Relapsed and Refractory AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Niclosamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 16, "start_date": "2022-11-21", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-09T18:29:36.469Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05188170" } ] }